Pursuant to Regulations 30 and 33 of SEBI (LODR) Regulations, 2015, Mesco Pharmaceuticals has informed about submission of the Standalone unaudited Financial Results and Limited Review Report for the quarter ended on 31st December, 2018, duly considered and approved by the Board of Directors in their Board Meeting held on Wednesday, 13th February, 2019 at New Delhi commenced at 02:00 pm and concluded at 02:50 pm.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1865.95 |
| Dr. Reddys Labs. | 1339.35 |
| Cipla | 1456.95 |
| Zydus Lifesciences | 1108.85 |
| Lupin | 2396.50 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: